A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of abiraterone acetate when co-administered with prednisone in Asian patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed docetaxel-based chemotherapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
This is a randomized (the treatment group is assigned by chance), double-blind (neither physician nor patient knows the treatment that the patient receives) placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study with a randomization allocation ratio of 2:1 between the abiraterone acetate group (abiraterone acetate plus prednisone) and the placebo group (placebo plus prednisone). Approximately 200 (133 in the abiraterone acetate group and 67 in the placebo group) medically or surgically castrated male patients with mCRPC who have failed docetaxel-based chemotherapy will be enrolled in this study for up to 27 months. The study protocol includes the following phases: screening (within 28 days prior to randomization on Cycle 1 Day 1), double-blind treatment (28-day cycles until protocol-defined disease progression or unacceptable toxicity), and survival follow-up (up to Month 60). During the follow-up phase, patients with disease progression will be provided open-label (identity of assigned study drug will be known) extension treatment with abiraterone acetate. In the event of a positive study result at the time of the final analysis, participants in the placebo group who have not shown progressive disease in the double-blind treatment Phase of the study will be enrolled in an open-label extension treatment with abiraterone acetate treatment based on the participant's choice and treating physician's endorsement if they meet the criteria for subsequent abiraterone acetate. Abiraterone acetate 1000 mg tablets or placebo will be taken orally (by mouth) once daily plus prednisone 5 mg tablet orally twice daily. Efficacy and safety will be monitored throughout the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Abiraterone acetate plus prednisone
|
Drug: Abiraterone acetate
Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
Drug: Prednisone
Prednisone 5 mg tablet taken orally twice daily
|
| Experimental: Placebo plus prednisone
|
Drug: Placebo
Placebo (4 tablets) taken orally once daily
Drug: Prednisone
Prednisone 5 mg tablet taken orally twice daily
|
Outcome Measures
Primary Outcome Measures
- DB Phase: Time to Prostate-Specific Antigen Progression (PSA) [Up to 1.8 years]
Time to PSA progression was defined as time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the Prostate Specific Antigen Working Group (PSAWG) criteria. PSAWG criteria- Decline from baseline and reach response criteria: greater than or equal to (>=) 50 percent (%) increase over the nadir and the increase in the absolute-value by at least 5 nanogram per milliliter (ng/mL) (or back to the baseline), which is confirmed by a second value 4 or more weeks later; Decline from baseline but not reach response criteria: >=25% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later; and No decline from baseline: >=25% increase over the baseline and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later.
Secondary Outcome Measures
- DB Phase: Overall Survival [From randomization to the date of death due to any cause (up to approximately 3.8 years)]
Overall survival was defined as the time interval from the date of randomization to the date of death from any cause.
- DB Phase: Percentage of Participants Who Achieved PSA Response [Approximately up to 3.8 years]
Percentage of participants who achieved PSA response (defined as >= 50% PSA decline from baseline) according to PSAWG criteria were reported. PSAWG criteria- Decline from baseline and reach response criteria: >= 50% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL (or back to the baseline), which is confirmed by a second value 4 or more weeks later; Decline from baseline but not reach response criteria: >=25% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later; and No decline from baseline: >=25% increase over the baseline and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later.
- DB Phase: Objective Response Rate (ORR) [Approximately up to 3.8 years]
ORR was defined as the percentage of participants with measurable disease at baseline achieving a complete response (CR) or partial response (PR) according to modified response evaluation criteria in solid tumors (RECIST) criteria. RECIST criteria for CR: disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
- DB Phase: Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire: Total Scores at the End of Treatment [Baseline, at End of Treatment (15 and 30 days after the last dose [up to 3.8 years])]
FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS) (Range 1-156, higher scores better). The FACT-General (FACT-G) is a 28 item Quality of Life (QOL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional (0-24) Well-being. The total range was between 1-108, higher scores better. Functional Assessment of Cancer Therapy-Treatment Outcome Index (FACT-TOI) is derived from the sum of the Physical Well-Being, Functional Well-Being, and Prostate Cancer subscale scores; a sensitive measure of patient-reported health (Range 1-104, higher scores better). PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better).
- DB Phase: Time to Pain Progression [Approximately up to 3.8 years]
Time to Pain progression calculated as number of days from date of randomization to date of pain progression. Pain progression- worsening of pain due to metastatic bone disease defined as increase of >=30% in worst pain over past 24 hours on BPI-SF numeric rating scale at 2 consecutive evaluations 4 weeks apart without decrease in analgesic usage score (in 2 corresponding consecutive evaluation in analgesic usage score, if there is missing visit, use existing visit only) or increase in analgesic usage score >=30% at 2 consecutive evaluations 4 weeks apart. BPI-SF is 11-item questionnaire which includes 4 questions that assess pain intensity and 7 questions that assess impact of pain on daily functions. Total score (average of individual questions) ranges from 0=No pain to 10=Pain as bad as you can imagine; Higher scores= greater pain. Analgesic usage was scored on scale of 0 to 3 where 0=no analgesic, 1=non-opioid analgesics, 2=opioids for moderate pain and 3=opioids for severe pain.
- DB Phase: Percentage of Participants Experiencing Pain Palliation [Approximately up to 3.8 years]
Percentage of participants experiencing pain palliation were reported. A participant is responder if experienced >=30% reduction in Brief Pain Inventory - Short Form (BPI-SF) worst pain intensity score over 24 hours observed at 2 consecutive evaluations 4 weeks apart without any increase in analgesic usage score (best response). Analgesic usage was scored on a scale of 0 to 3 where 0=no analgesic, 1=non-opioid analgesics, 2=opioids for moderate pain and 3=opioids for severe pain. BPI-SF is 11-item self-reported questionnaire designed to assess severity and impact of pain on daily functions. It includes 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Total score (average of individual questions) ranges from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain.
- DB Phase: Change From Baseline in Brief Fatigue Inventory (BFI) Score at End of Treatment [Baseline, at End of Treatment (15 and 30 days after the last dose [up to 3.8 years])]
The Brief Fatigue Inventory (BFI) is a brief participant-reported questionnaire that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. BFI has nine items. Three items ask patients to rate the severity of their fatigue at its "worst," "usual," and "now" during normal waking hours, with 0 being "no fatigue" and 10 being "fatigue as bad as you can imagine." Six items assess the amount that fatigue has interfered with different aspects of the patient's life during the past 24 hours. The interference items include general activity, mood, walking ability, normal work (includes both work outside the home and housework), relations with other people, and enjoyment of life. The interference items are measured on a 0-10 scale, with 0 being "does not interfere" and 10 being "completely interferes." BFI Total Score is the average of the nine items, ranging from 0 (no fatigue) to 10 (high fatigue).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically or cytologically confirmed adenocarcinoma of the prostate except neuroendocrine carcinoma including small cell carcinoma
-
Disease progressed on or after prior docetaxel-containing chemotherapy
-
Prior 1 or 2 cytotoxic chemotherapy regimens for metastatic castration-resistant prostate cancer, at least 1 of which contains docetaxel
-
Documented prostate cancer progression as documented by prostate specific antigen progression according to Prostate Specific Antigen Working Group criteria or radiographic progression in soft tissue or bone
-
Surgically or medically castrated, with serum testosterone level <50 ng/dL (1.7 nmol/L)
-
Eastern Cooperative Oncology Group performance status score of <=2
-
Protocol-defined laboratory values
-
Agrees to protocol-defined use of effective contraception
Exclusion Criteria:
-
Active infection or other medical condition that would make prednisone (corticosteroid) use contraindicated
-
Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone twice daily
-
Pathological finding consistent with neuroendocrine carcinoma of prostate including small cell carcinoma
-
Uncontrolled hypertension (systolic BP >=160 mmHg or diastolic BP >=95 mmHg; patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy)
-
Active or symptomatic viral hepatitis or chronic liver disease, have a known infection with human immunodeficiency virus and/or hepatitis B virus or hepatitis C virus
-
History of pituitary or adrenal dysfunction.
-
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association Class III or IV heart disease or cardiac ejection fraction measurement of <50% at baseline
-
Atrial fibrillation, or other cardiac arrhythmia requiring therapy
-
Other malignancy within past 3 years (except basal or nonmetastatic squamous cell carcinoma of the skin)
-
Known brain metastasis
-
Prior therapy with abiraterone acetate or other CYP17 inhibitor(s), or investigational agent(s) targeting the androgen receptor for metastatic prostate cancer
-
Prior therapy with ketoconazole for prostate cancer
-
Surgery or local prostatic intervention within 30 days of the first dose
-
Radiotherapy, chemotherapy, or immunotherapy within 30 days, or single fraction of palliative radiotherapy within 14 days of administration of Cycle 1 Day 1
-
Any acute toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to a National Cancer Institute-Common Terminology Criteria for Adverse Events grade of <=1 (chemotherapy induced alopecia and grade 2 peripheral neuropathy is allowed)
-
Current enrollment in an investigational drug or device study or participation in such a study within 30 days of Cycle 1 Day 1
-
Anti-androgen treatment must not be given within 4 weeks (flutamide) or 6 weeks (bicalutamide or nilutamide) prior to Cycle 1 Day 1
-
Prior systemic treatment with an azole drug (eg, fluconazole, itraconazole) within 4 weeks prior to Cycle 1 Day 1
-
Has known allergies, hypersensitivity, or intolerance to abiraterone acetate or its excipients
-
Has contraindications to the use of prednisone per local prescribing information
-
Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beijing | China | |||
| 2 | Changsha | China | |||
| 3 | Chongqing | China | |||
| 4 | Guangzhou | China | |||
| 5 | Hangzhou | China | |||
| 6 | Nanjing | China | |||
| 7 | Shanghai | China | |||
| 8 | Su Zhou | China | |||
| 9 | Tianjin | China | |||
| 10 | Wenzhou | China | |||
| 11 | Wuhan | China |
Sponsors and Collaborators
- Janssen Research & Development, LLC
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CR100010
- ABI-PRO-3001
Study Results
Participant Flow
| Recruitment Details | A total of 214 participants were enrolled in the study (143 participants in abiraterone acetate group and 71 participants in placebo group). |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Placebo + Prednisone (Double-blind [DB]) | Abiraterone Acetate + Prednisone (Double-blind) | Placebo + Prednisone (DB) to AA + Prednisone (Open-label) | AA + Prednisone to AA + Prednisone (Open-label) |
|---|---|---|---|---|
| Arm/Group Description | Participants received placebo (4 tablets) once daily + prednisone 5 milligram (mg) twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants received abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily + prednisone 5 mg twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants with disease progression during the double-blind treatment phase received abiraterone acetate 1000 mg once daily + prednisone 5 mg twice daily in open-label extension treatment phase based on the participant's choice and treating physician's decision if they met the criteria for subsequent abiraterone acetate treatment until they no longer derive clinical benefit, unacceptable toxicity, initiation of a subsequent anticancer therapy, or serious protocol violation. | Participants with disease progression during the double-blind treatment phase received abiraterone acetate 1000 mg once daily + prednisone 5 mg twice daily in open-label extension treatment phase based on the participant's choice and treating physician's decision if they met the criteria for subsequent abiraterone acetate treatment until they no longer derive clinical benefit, unacceptable toxicity, initiation of a subsequent anticancer therapy, or serious protocol violation. |
| Period Title: Double-blind Treatment Phase | ||||
| STARTED | 71 | 143 | 0 | 0 |
| COMPLETED | 0 | 4 | 0 | 0 |
| NOT COMPLETED | 71 | 139 | 0 | 0 |
| Period Title: Double-blind Treatment Phase | ||||
| STARTED | 0 | 0 | 49 | 80 |
| COMPLETED | 0 | 0 | 9 | 10 |
| NOT COMPLETED | 0 | 0 | 40 | 70 |
Baseline Characteristics
| Arm/Group Title | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) | Total |
|---|---|---|---|
| Arm/Group Description | Participants received placebo (4 tablets) once daily + prednisone 5 milligram (mg) twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants received abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily + prednisone 5 mg twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Total of all reporting groups |
| Overall Participants | 71 | 143 | 214 |
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
67.7
(7.75)
|
68.2
(8.3)
|
68
(8.11)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
0
0%
|
0
0%
|
0
0%
|
| Male |
71
100%
|
143
100%
|
214
100%
|
| Race/Ethnicity, Customized (Count of Participants) | |||
| Asian |
71
100%
|
143
100%
|
214
100%
|
| Region of Enrollment (Count of Participants) | |||
| China |
71
100%
|
143
100%
|
214
100%
|
Outcome Measures
| Title | DB Phase: Time to Prostate-Specific Antigen Progression (PSA) |
|---|---|
| Description | Time to PSA progression was defined as time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the Prostate Specific Antigen Working Group (PSAWG) criteria. PSAWG criteria- Decline from baseline and reach response criteria: greater than or equal to (>=) 50 percent (%) increase over the nadir and the increase in the absolute-value by at least 5 nanogram per milliliter (ng/mL) (or back to the baseline), which is confirmed by a second value 4 or more weeks later; Decline from baseline but not reach response criteria: >=25% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later; and No decline from baseline: >=25% increase over the baseline and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later. |
| Time Frame | Up to 1.8 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| Intent-to-Treat (ITT) analysis set included all participants randomized into the study and classified according to their assigned treatment group, regardless of the actual treatment received. |
| Arm/Group Title | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| Arm/Group Description | Participants received placebo (4 tablets) once daily + prednisone 5 milligram (mg) twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants received abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily + prednisone 5 mg twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. |
| Measure Participants | 71 | 143 |
| Median (95% Confidence Interval) [Days] |
84.00
|
169.00
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Placebo + Prednisone (Double-blind), Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Superiority | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.0002 |
| Comments | ||
| Method | Log Rank | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
| Estimated Value | 0.528 | |
| Confidence Interval |
(2-Sided) 95% 0.376 to 0.740 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | DB Phase: Overall Survival |
|---|---|
| Description | Overall survival was defined as the time interval from the date of randomization to the date of death from any cause. |
| Time Frame | From randomization to the date of death due to any cause (up to approximately 3.8 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT analysis set included all participants randomized into the study and classified according to their assigned treatment group, regardless of the actual treatment received. |
| Arm/Group Title | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| Arm/Group Description | Participants received placebo (4 tablets) once daily + prednisone 5 milligram (mg) twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants received abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily + prednisone 5 mg twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. |
| Measure Participants | 71 | 143 |
| Median (95% Confidence Interval) [Days] |
561.00
|
579.00
|
| Title | DB Phase: Percentage of Participants Who Achieved PSA Response |
|---|---|
| Description | Percentage of participants who achieved PSA response (defined as >= 50% PSA decline from baseline) according to PSAWG criteria were reported. PSAWG criteria- Decline from baseline and reach response criteria: >= 50% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL (or back to the baseline), which is confirmed by a second value 4 or more weeks later; Decline from baseline but not reach response criteria: >=25% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later; and No decline from baseline: >=25% increase over the baseline and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later. |
| Time Frame | Approximately up to 3.8 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT analysis set included all participants randomized into the study and classified according to their assigned treatment group, regardless of the actual treatment received. |
| Arm/Group Title | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| Arm/Group Description | Participants received placebo (4 tablets) once daily + prednisone 5 milligram (mg) twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants received abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily + prednisone 5 mg twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. |
| Measure Participants | 71 | 143 |
| Number [Percentage of Participants] |
18.3
25.8%
|
54.5
38.1%
|
| Title | DB Phase: Objective Response Rate (ORR) |
|---|---|
| Description | ORR was defined as the percentage of participants with measurable disease at baseline achieving a complete response (CR) or partial response (PR) according to modified response evaluation criteria in solid tumors (RECIST) criteria. RECIST criteria for CR: disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. |
| Time Frame | Approximately up to 3.8 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT analysis set included all participants randomized into the study and classified according to their assigned treatment group, regardless of the actual treatment received. Population included only participants with measurable disease at baseline. |
| Arm/Group Title | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| Arm/Group Description | Participants received placebo (4 tablets) once daily + prednisone 5 milligram (mg) twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants received abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily + prednisone 5 mg twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. |
| Measure Participants | 24 | 57 |
| Number [Percentage of Participants] |
4.2
5.9%
|
17.5
12.2%
|
| Title | DB Phase: Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire: Total Scores at the End of Treatment |
|---|---|
| Description | FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS) (Range 1-156, higher scores better). The FACT-General (FACT-G) is a 28 item Quality of Life (QOL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional (0-24) Well-being. The total range was between 1-108, higher scores better. Functional Assessment of Cancer Therapy-Treatment Outcome Index (FACT-TOI) is derived from the sum of the Physical Well-Being, Functional Well-Being, and Prostate Cancer subscale scores; a sensitive measure of patient-reported health (Range 1-104, higher scores better). PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). |
| Time Frame | Baseline, at End of Treatment (15 and 30 days after the last dose [up to 3.8 years]) |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT analysis set included all participants randomized into the study and classified according to their assigned treatment group, regardless of the actual treatment received. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. |
| Arm/Group Title | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| Arm/Group Description | Participants received placebo (4 tablets) once daily + prednisone 5 milligram (mg) twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants received abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily + prednisone 5 mg twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. |
| Measure Participants | 52 | 97 |
| Total Score |
-19.9
(22.07)
|
-16.1
(22.74)
|
| Physical Well-being |
-6.7
(6.52)
|
-4.9
(6.85)
|
| Functional Well-being |
-5.1
(6.60)
|
-2.7
(7.31)
|
| Emotional Well-being |
-2.1
(4.48)
|
-2.4
(4.87)
|
| Social Well-being |
-0.8
(3.82)
|
-1.2
(6.55)
|
| FACT-G Total Score |
-14.6
(16.25)
|
-11.2
(17.19)
|
| Prostate Cancer Subscale (PCS) |
-5.3
(7.99)
|
-4.9
(7.70)
|
| Treatment Outcome Index (FACT-TOI) |
-17.1
(17.76)
|
-12.5
(17.52)
|
| Title | DB Phase: Time to Pain Progression |
|---|---|
| Description | Time to Pain progression calculated as number of days from date of randomization to date of pain progression. Pain progression- worsening of pain due to metastatic bone disease defined as increase of >=30% in worst pain over past 24 hours on BPI-SF numeric rating scale at 2 consecutive evaluations 4 weeks apart without decrease in analgesic usage score (in 2 corresponding consecutive evaluation in analgesic usage score, if there is missing visit, use existing visit only) or increase in analgesic usage score >=30% at 2 consecutive evaluations 4 weeks apart. BPI-SF is 11-item questionnaire which includes 4 questions that assess pain intensity and 7 questions that assess impact of pain on daily functions. Total score (average of individual questions) ranges from 0=No pain to 10=Pain as bad as you can imagine; Higher scores= greater pain. Analgesic usage was scored on scale of 0 to 3 where 0=no analgesic, 1=non-opioid analgesics, 2=opioids for moderate pain and 3=opioids for severe pain. |
| Time Frame | Approximately up to 3.8 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT analysis set included all participants randomized into the study and classified according to their assigned treatment group, regardless of the actual treatment received. |
| Arm/Group Title | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| Arm/Group Description | Participants received placebo (4 tablets) once daily + prednisone 5 milligram (mg) twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants received abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily + prednisone 5 mg twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. |
| Measure Participants | 71 | 143 |
| Median (95% Confidence Interval) [Days] |
169.00
|
505.00
|
| Title | DB Phase: Percentage of Participants Experiencing Pain Palliation |
|---|---|
| Description | Percentage of participants experiencing pain palliation were reported. A participant is responder if experienced >=30% reduction in Brief Pain Inventory - Short Form (BPI-SF) worst pain intensity score over 24 hours observed at 2 consecutive evaluations 4 weeks apart without any increase in analgesic usage score (best response). Analgesic usage was scored on a scale of 0 to 3 where 0=no analgesic, 1=non-opioid analgesics, 2=opioids for moderate pain and 3=opioids for severe pain. BPI-SF is 11-item self-reported questionnaire designed to assess severity and impact of pain on daily functions. It includes 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Total score (average of individual questions) ranges from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain. |
| Time Frame | Approximately up to 3.8 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT analysis set included all participants randomized into the study and classified according to their assigned treatment group, regardless of the actual treatment received. Population included only participants whose pain score was >= 4 at baseline. |
| Arm/Group Title | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| Arm/Group Description | Participants received placebo (4 tablets) once daily + prednisone 5 milligram (mg) twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants received abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily + prednisone 5 mg twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. |
| Measure Participants | 22 | 55 |
| Number [Percentage of Participants] |
31.8
44.8%
|
54.5
38.1%
|
| Title | DB Phase: Change From Baseline in Brief Fatigue Inventory (BFI) Score at End of Treatment |
|---|---|
| Description | The Brief Fatigue Inventory (BFI) is a brief participant-reported questionnaire that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. BFI has nine items. Three items ask patients to rate the severity of their fatigue at its "worst," "usual," and "now" during normal waking hours, with 0 being "no fatigue" and 10 being "fatigue as bad as you can imagine." Six items assess the amount that fatigue has interfered with different aspects of the patient's life during the past 24 hours. The interference items include general activity, mood, walking ability, normal work (includes both work outside the home and housework), relations with other people, and enjoyment of life. The interference items are measured on a 0-10 scale, with 0 being "does not interfere" and 10 being "completely interferes." BFI Total Score is the average of the nine items, ranging from 0 (no fatigue) to 10 (high fatigue). |
| Time Frame | Baseline, at End of Treatment (15 and 30 days after the last dose [up to 3.8 years]) |
Outcome Measure Data
| Analysis Population Description |
|---|
| ITT analysis set included all participants randomized into the study and classified according to their assigned treatment group, regardless of the actual treatment received. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. |
| Arm/Group Title | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| Arm/Group Description | Participants received placebo (4 tablets) once daily + prednisone 5 milligram (mg) twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants received abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily + prednisone 5 mg twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. |
| Measure Participants | 52 | 98 |
| Fatigue Now |
2.4
(3.59)
|
1.7
(3.34)
|
| Usual Fatigue |
2.4
(3.53)
|
1.5
(3.18)
|
| Worst Fatigue |
2.6
(3.73)
|
1.6
(3.49)
|
| General Activity |
2.3
(3.65)
|
1.7
(3.38)
|
| Mood |
2.7
(3.39)
|
1.8
(3.40)
|
| Walking Ability |
2.4
(3.28)
|
1.8
(3.50)
|
| Normal Work |
2.2
(3.84)
|
2.0
(3.71)
|
| Relations with Other People |
2.0
(3.08)
|
1.6
(3.25)
|
| Enjoyment of Life |
2.5
(3.33)
|
1.9
(3.64)
|
Adverse Events
| Time Frame | Approximately up to 3.8 years | |||||||
|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | Safety analysis set included all randomized participants who received at least one dose of study drug and classified to the treatment group according to their actual treatment received. | |||||||
| Arm/Group Title | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) | Placebo + Prednisone (DB) to AA + Prednisone (Open-label) | AA + Prednisone to AA + Prednisone (Open-label) | ||||
| Arm/Group Description | Participants received placebo (4 tablets) once daily + prednisone 5 milligram (mg) twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants received abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily + prednisone 5 mg twice daily on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Each cycle of 28 days. | Participants with disease progression during the double-blind treatment phase received abiraterone acetate 1000 mg once daily + prednisone 5 mg twice daily in open-label extension treatment phase based on the participant's choice and treating physician's decision if they met the criteria for subsequent abiraterone acetate treatment until they no longer derive clinical benefit, unacceptable toxicity, initiation of a subsequent anticancer therapy, or serious protocol violation. | Participants with disease progression during the double-blind treatment phase received abiraterone acetate 1000 mg once daily + prednisone 5 mg twice daily in open-label extension treatment phase based on the participant's choice and treating physician's decision if they met the criteria for subsequent abiraterone acetate treatment until they no longer derive clinical benefit, unacceptable toxicity, initiation of a subsequent anticancer therapy, or serious protocol violation. | ||||
All Cause Mortality |
||||||||
| Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) | Placebo + Prednisone (DB) to AA + Prednisone (Open-label) | AA + Prednisone to AA + Prednisone (Open-label) | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | / (NaN) | / (NaN) | ||||
Serious Adverse Events |
||||||||
| Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) | Placebo + Prednisone (DB) to AA + Prednisone (Open-label) | AA + Prednisone to AA + Prednisone (Open-label) | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 20/71 (28.2%) | 33/143 (23.1%) | 25/49 (51%) | 41/80 (51.3%) | ||||
| Blood and lymphatic system disorders | ||||||||
| Anaemia | 0/71 (0%) | 3/143 (2.1%) | 2/49 (4.1%) | 5/80 (6.3%) | ||||
| Disseminated intravascular coagulation | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Thrombocytopenia | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Cardiac disorders | ||||||||
| Cardiac disorder | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Cardiac failure | 0/71 (0%) | 1/143 (0.7%) | 1/49 (2%) | 1/80 (1.3%) | ||||
| Acute myocardial infarction | 1/71 (1.4%) | 0/143 (0%) | 1/49 (2%) | 1/80 (1.3%) | ||||
| Coronary artery disease | 1/71 (1.4%) | 0/143 (0%) | 0/49 (0%) | 0/80 (0%) | ||||
| Myocardial infarction | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Eye disorders | ||||||||
| Blindness | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Blindness unilateral | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Cataract | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| Gastrointestinal disorders | ||||||||
| Gastrointestinal disorder | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Gastrointestinal motility disorder | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Intestinal obstruction | 1/71 (1.4%) | 1/143 (0.7%) | 1/49 (2%) | 0/80 (0%) | ||||
| Pancreatitis acute | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Diarrhoea | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| Enterovesical fistula | 1/71 (1.4%) | 0/143 (0%) | 0/49 (0%) | 0/80 (0%) | ||||
| Gastritis | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Vomiting | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| General disorders | ||||||||
| Disease progression | 5/71 (7%) | 6/143 (4.2%) | 8/49 (16.3%) | 17/80 (21.3%) | ||||
| Chest discomfort | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Multi-organ failure | 0/71 (0%) | 1/143 (0.7%) | 2/49 (4.1%) | 3/80 (3.8%) | ||||
| Oedema peripheral | 1/71 (1.4%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Pyrexia | 1/71 (1.4%) | 1/143 (0.7%) | 1/49 (2%) | 4/80 (5%) | ||||
| Death | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 2/80 (2.5%) | ||||
| Fatigue | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| Pain | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Sudden death | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| Hepatobiliary disorders | ||||||||
| Jaundice cholestatic | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Hepatic function abnormal | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| Infections and infestations | ||||||||
| Lung infection | 0/71 (0%) | 2/143 (1.4%) | 3/49 (6.1%) | 4/80 (5%) | ||||
| Biliary tract infection | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Bronchitis | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Kidney infection | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Pneumonia | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Pulpitis dental | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Pyelonephritis acute | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Respiratory tract infection | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Septic shock | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Urinary tract infection | 0/71 (0%) | 1/143 (0.7%) | 1/49 (2%) | 0/80 (0%) | ||||
| Herpes zoster | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| Upper respiratory tract infection | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| Injury, poisoning and procedural complications | ||||||||
| Femur fracture | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Hip fracture | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Spinal compression fracture | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Fracture | 1/71 (1.4%) | 0/143 (0%) | 0/49 (0%) | 0/80 (0%) | ||||
| Investigations | ||||||||
| Alanine aminotransferase increased | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| Aspartate aminotransferase increased | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| Platelet count decreased | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 2/80 (2.5%) | ||||
| Metabolism and nutrition disorders | ||||||||
| Dehydration | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Ketoacidosis | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Decreased appetite | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| Hypoglycaemia | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Malnutrition | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Musculoskeletal and connective tissue disorders | ||||||||
| Bone pain | 2/71 (2.8%) | 3/143 (2.1%) | 2/49 (4.1%) | 3/80 (3.8%) | ||||
| Back pain | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Musculoskeletal disorder | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Pain in extremity | 0/71 (0%) | 1/143 (0.7%) | 1/49 (2%) | 0/80 (0%) | ||||
| Pathological fracture | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Spinal disorder | 1/71 (1.4%) | 0/143 (0%) | 0/49 (0%) | 0/80 (0%) | ||||
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||||||
| Bladder cancer | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Metastases to lung | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Squamous cell carcinoma of lung | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Colon cancer | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Nervous system disorders | ||||||||
| Cerebral infarction | 1/71 (1.4%) | 1/143 (0.7%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Spinal cord compression | 1/71 (1.4%) | 1/143 (0.7%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Viith nerve paralysis | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Coma | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| Dyskinesia | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Renal and urinary disorders | ||||||||
| Haematuria | 1/71 (1.4%) | 1/143 (0.7%) | 1/49 (2%) | 0/80 (0%) | ||||
| Hydronephrosis | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Renal failure | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Renal failure acute | 1/71 (1.4%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Ureteric obstruction | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Urethral haemorrhage | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Urinary bladder haemorrhage | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Urinary retention | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Reproductive system and breast disorders | ||||||||
| Prostatic haemorrhage | 1/71 (1.4%) | 0/143 (0%) | 0/49 (0%) | 0/80 (0%) | ||||
| Respiratory, thoracic and mediastinal disorders | ||||||||
| Chronic obstructive pulmonary disease | 1/71 (1.4%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
| Haemoptysis | 1/71 (1.4%) | 0/143 (0%) | 0/49 (0%) | 0/80 (0%) | ||||
| Pleural effusion | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Pulmonary embolism | 1/71 (1.4%) | 0/143 (0%) | 0/49 (0%) | 0/80 (0%) | ||||
| Respiratory failure | 2/71 (2.8%) | 0/143 (0%) | 0/49 (0%) | 2/80 (2.5%) | ||||
| Sleep apnoea syndrome | 1/71 (1.4%) | 0/143 (0%) | 0/49 (0%) | 0/80 (0%) | ||||
| Vascular disorders | ||||||||
| Hypotension | 0/71 (0%) | 2/143 (1.4%) | 0/49 (0%) | 0/80 (0%) | ||||
| Peripheral embolism | 0/71 (0%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Circulatory collapse | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Deep vein thrombosis | 0/71 (0%) | 0/143 (0%) | 0/49 (0%) | 1/80 (1.3%) | ||||
| Haemorrhagic infarction | 1/71 (1.4%) | 0/143 (0%) | 0/49 (0%) | 0/80 (0%) | ||||
| Thrombosis | 0/71 (0%) | 0/143 (0%) | 1/49 (2%) | 0/80 (0%) | ||||
Other (Not Including Serious) Adverse Events |
||||||||
| Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) | Placebo + Prednisone (DB) to AA + Prednisone (Open-label) | AA + Prednisone to AA + Prednisone (Open-label) | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 62/71 (87.3%) | 134/143 (93.7%) | 35/49 (71.4%) | 54/80 (67.5%) | ||||
| Blood and lymphatic system disorders | ||||||||
| Anaemia | 16/71 (22.5%) | 38/143 (26.6%) | 13/49 (26.5%) | 29/80 (36.3%) | ||||
| Gastrointestinal disorders | ||||||||
| Constipation | 5/71 (7%) | 12/143 (8.4%) | 2/49 (4.1%) | 4/80 (5%) | ||||
| Nausea | 3/71 (4.2%) | 5/143 (3.5%) | 1/49 (2%) | 4/80 (5%) | ||||
| Vomiting | 6/71 (8.5%) | 4/143 (2.8%) | 3/49 (6.1%) | 3/80 (3.8%) | ||||
| General disorders | ||||||||
| Fatigue | 5/71 (7%) | 13/143 (9.1%) | 1/49 (2%) | 1/80 (1.3%) | ||||
| Pyrexia | 3/71 (4.2%) | 12/143 (8.4%) | 3/49 (6.1%) | 5/80 (6.3%) | ||||
| Oedema peripheral | 9/71 (12.7%) | 10/143 (7%) | 2/49 (4.1%) | 5/80 (6.3%) | ||||
| Pain | 4/71 (5.6%) | 1/143 (0.7%) | 0/49 (0%) | 0/80 (0%) | ||||
| Hepatobiliary disorders | ||||||||
| Hyperbilirubinaemia | 1/71 (1.4%) | 5/143 (3.5%) | 4/49 (8.2%) | 2/80 (2.5%) | ||||
| Infections and infestations | ||||||||
| Urinary tract infection | 6/71 (8.5%) | 13/143 (9.1%) | 6/49 (12.2%) | 7/80 (8.8%) | ||||
| Upper respiratory tract infection | 5/71 (7%) | 10/143 (7%) | 4/49 (8.2%) | 4/80 (5%) | ||||
| Investigations | ||||||||
| Aspartate aminotransferase increased | 12/71 (16.9%) | 29/143 (20.3%) | 7/49 (14.3%) | 9/80 (11.3%) | ||||
| Alanine aminotransferase increased | 9/71 (12.7%) | 20/143 (14%) | 6/49 (12.2%) | 5/80 (6.3%) | ||||
| Blood lactate dehydrogenase increased | 6/71 (8.5%) | 10/143 (7%) | 3/49 (6.1%) | 3/80 (3.8%) | ||||
| Blood albumin decreased | 4/71 (5.6%) | 8/143 (5.6%) | 0/49 (0%) | 2/80 (2.5%) | ||||
| Weight decreased | 3/71 (4.2%) | 8/143 (5.6%) | 3/49 (6.1%) | 9/80 (11.3%) | ||||
| Blood alkaline phosphatase increased | 6/71 (8.5%) | 6/143 (4.2%) | 2/49 (4.1%) | 3/80 (3.8%) | ||||
| Platelet count decreased | 2/71 (2.8%) | 6/143 (4.2%) | 4/49 (8.2%) | 6/80 (7.5%) | ||||
| White blood cell count decreased | 3/71 (4.2%) | 3/143 (2.1%) | 4/49 (8.2%) | 3/80 (3.8%) | ||||
| Blood phosphorus decreased | 0/71 (0%) | 2/143 (1.4%) | 0/49 (0%) | 4/80 (5%) | ||||
| Gamma-glutamyltransferase increased | 0/71 (0%) | 2/143 (1.4%) | 2/49 (4.1%) | 7/80 (8.8%) | ||||
| White blood cells urine positive | 0/71 (0%) | 1/143 (0.7%) | 3/49 (6.1%) | 0/80 (0%) | ||||
| Metabolism and nutrition disorders | ||||||||
| Hypokalaemia | 10/71 (14.1%) | 39/143 (27.3%) | 8/49 (16.3%) | 14/80 (17.5%) | ||||
| Hyperglycaemia | 6/71 (8.5%) | 17/143 (11.9%) | 4/49 (8.2%) | 6/80 (7.5%) | ||||
| Decreased appetite | 9/71 (12.7%) | 3/143 (2.1%) | 4/49 (8.2%) | 2/80 (2.5%) | ||||
| Hypoalbuminaemia | 6/71 (8.5%) | 3/143 (2.1%) | 1/49 (2%) | 0/80 (0%) | ||||
| Musculoskeletal and connective tissue disorders | ||||||||
| Bone pain | 15/71 (21.1%) | 36/143 (25.2%) | 6/49 (12.2%) | 4/80 (5%) | ||||
| Back pain | 9/71 (12.7%) | 20/143 (14%) | 5/49 (10.2%) | 4/80 (5%) | ||||
| Arthralgia | 5/71 (7%) | 17/143 (11.9%) | 2/49 (4.1%) | 0/80 (0%) | ||||
| Pain in extremity | 11/71 (15.5%) | 17/143 (11.9%) | 2/49 (4.1%) | 1/80 (1.3%) | ||||
| Musculoskeletal pain | 5/71 (7%) | 10/143 (7%) | 1/49 (2%) | 3/80 (3.8%) | ||||
| Nervous system disorders | ||||||||
| Hypoaesthesia | 3/71 (4.2%) | 9/143 (6.3%) | 3/49 (6.1%) | 1/80 (1.3%) | ||||
| Renal and urinary disorders | ||||||||
| Haematuria | 4/71 (5.6%) | 9/143 (6.3%) | 2/49 (4.1%) | 1/80 (1.3%) | ||||
| Proteinuria | 5/71 (7%) | 9/143 (6.3%) | 0/49 (0%) | 0/80 (0%) | ||||
| Respiratory, thoracic and mediastinal disorders | ||||||||
| Cough | 2/71 (2.8%) | 7/143 (4.9%) | 3/49 (6.1%) | 0/80 (0%) | ||||
| Vascular disorders | ||||||||
| Hypertension | 9/71 (12.7%) | 22/143 (15.4%) | 3/49 (6.1%) | 4/80 (5%) | ||||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.
Results Point of Contact
| Name/Title | Senior Director |
|---|---|
| Organization | Janssen Research & Development, LLC |
| Phone | 844-434-4210 |
| ClinicalTrialDisclosure@its.jnj.com |
- CR100010
- ABI-PRO-3001